

## Publikationsliste Univ.-Klinik für Nuklearmedizin 2018-2019

---

1. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Klingler M, Rangger C, Summer D, Kaeopookum P, Decristoforo C, von Guggenberg E. Pharmaceuticals (Basel). 2019 Jan 15;12(1). pii: E13.
2. Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, Virgolini IJ. <sup>68</sup>Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with <sup>18</sup>F-DOPA PET/CT. Rev Esp Med Nucl Imagen Mol. 2019 Jan 7. pii: S2253-654X(18)30163-X. [Epub ahead of print].
3. Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Virgolini I, Decristoforo C, von Guggenberg E. DOTA-MGS5, a new cholecystokinin-2 receptor targeting peptide analog with optimized targeting profile for theranostic use. J Nucl Med. 2018 Dec 7. pii: jnumed.118.221283. doi: 10.2967/jnumed.118.221283. [Epub ahead of print]
4. Erba PA, Maecke H, Mikolajczak R, Decristoforo C, Zaletel K, Maina-Nock T, Peitl PK, Garnuszek P, Froberg A, Goebel G, de Jong M, Jabrocka-Hybel A, Konijnenberg M, Virgolini I, Nock B, Lenda-Tracz W, Pawlak D, Rangger C, Trofimiuk-Müldner M, Sowa-Staszczak A, Tomaszuk M, von Guggenberg E, Scarpa L, Hubalewska-Dydejczyk A. A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study. Pol Arch Intern Med. 2018 Dec 21;128(12):791-795.
5. Gabriel M, Nilica B, Kaiser B, Virgolini IJ. Twelve-year Follow-up after Peptide Receptor Radionuclide Therapy (PRRT). J Nucl Med. 2018 Aug 16. pii: jnumed.118.215376. doi: 10.2967/jnumed.118.215376. [Epub ahead of print]
6. Martini C, Buxbaum S, Rodrigues M, Nilica B, Scarpa L, Holzner B, Virgolini I, Gamper EM. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine. J Nucl Med. 2018 Oct;59(10):1566-1573.
7. Haeusler D, Decristoforo C, Frost J, Gobalakrishnan S, Huang YY. Molecular Imaging: In Vivo Agents for the Diagnosis and Treatment of Cancer. Contrast Media Mol Imaging. 2018 Oct 22;2018:8541915.
8. Summer D, Mayr S, Petrik M, Rangger C, Schoeler K, Vieider L, Matuszczak B, Decristoforo C. Pretargeted Imaging with Gallium-68-Improving the Binding Capability by Increasing the Number of Tetrazine Motifs. Pharmaceuticals (Basel). 2018 Oct 11;11(4). pii: E102.
9. Kroiss AS, Uprimny C, Pichler R, Gasser RW, Virgolini IJ. A rare case of a <sup>123</sup>I-MIBG SPECT/CT positive, but <sup>68</sup>Ga-DOTA-TOC PET/CT negative pheochromocytoma of the bladder. Rev Esp Med Nucl Imagen Mol. 2018 Sep - Oct;37(5):315-317.
10. Petrik M, Umlaufova E, Raclavsky V, Palyzova A, Havlicek V, Haas H, Novy Z, Dolezal D, Hajduch M, Decristoforo C. Imaging of Pseudomonas aeruginosa infection with Ga-68 labelled pyoverdine for positron emission tomography. Sci Rep. 2018 Oct 24;8(1):15698.

11. Schwarz SW, Decristoforo C, Goodbody AE, Singhal N, Saliba S, Ruddock P, Zukotynski K, Ross AA. Harmonization of United States, European Union and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals-Is This Possible? *J Nucl Med*. 2018 Sep 27. pii: jnumed.118.209460. doi: 10.2967/jnumed.118.209460. [Epub ahead of print]
12. Mair C, Warwitz B, Fink K, Scarpa L, Nilica B, Maffey-Steffan J, Buxbaum S, Virgolini IJ. Radiation exposure after <sup>177</sup>Lu-DOTATATE and <sup>177</sup>Lu-PSMA-617 therapy. *Ann Nucl Med*. 2018 Aug;32(7):499-502.
13. Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ. Comparison of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT with [<sup>18</sup>F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. *Eur J Nucl Med Mol Imaging*. 2018 Oct;45(11):1873-1883. doi: 10.1007/s00259-018-4048-6. Epub 2018 May 16.
14. Maffey-Steffan J, Uprimny C, Moncayo R, Kroiss AS, Virgolini IJ. Usefulness of combined imaging with <sup>68</sup>Ga-DOTATOC PET/CT and spleen scintigraphy in differentiating a neuroendocrine tumour of the pancreatic tail from splenic lesions in a patient with posttraumatic splenosis. *Rev Esp Med Nucl Imagen Mol*. 2018 Sep - Oct;37(5):325-327.
15. Summer D, Kroess A, Woerndle R, Rangger C, Klingler M, Haas H, Kremser L, Lindner HH, von Guggenberg E, Decristoforo C. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression. *PLoS One*. 2018 Jul 30;13(7):e0201224. doi: 10.1371/journal.pone.0201224. eCollection 2018.
16. Vall-Sagarra A, Litau S, Decristoforo C, Wängler B, Schirmacher R, Fricker G, Wängler C. Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y<sub>1</sub>)- and GRP-Receptors-An Improvement for Breast Cancer Imaging? *Pharmaceuticals (Basel)*. 2018 Jul 4;11(3). pii: E65.
17. Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystinin-2 receptor targeting. *Theranostics*. 2018 Apr 16;8(11):2896-2908.
18. Summer D, Rangger C, Klingler M, Laverman P, Franssen GM, Lechner BE, Orasch T, Haas H, von Guggenberg E, Decristoforo C. Exploiting the Concept of Multivalency with <sup>68</sup>Ga- and <sup>89</sup>Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression. *Contrast Media Mol Imaging*. 2018 Apr 10;2018:3171794.
19. Fanti S, Bonfiglioli R, Decristoforo C. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can - make nuclear medicine great again". *Eur J Nucl Med Mol Imaging*. 2018 Sep;45(10):1781-1794. Review.
20. Lobeek D, Franssen GM, Ma MT, Wester HJ, Decristoforo C, Oyen WJG, Boerman OC, Terry SYA, Rijpkema M. In Vivo Characterization of 4 <sup>68</sup>Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models. *J Nucl Med*. 2018 Aug;59(8):1296-1301.
21. Virgolini I. Greetings from the New President of the World Association of Radiopharmaceutical and Molecular Therapy. *World J Nucl Med*. 2018 Apr-Jun;17(2):67-69.

22. Loth FL, Meraner V, Holzner B, Singer S, Virgolini I, Gamper EM. Following patient pathways to psycho-oncological treatment: Identification of treatment needs by clinical staff and electronic screening. *Psychooncology*. 2018 Apr;27(4):1312-1319. doi: 10.1002/pon.4675. Epub 2018 Mar 24.
23. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Eur Current status of theranostics in prostate cancer. *J Nucl Med Mol Imaging*. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28. Review.
24. von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. Third-line treatment and <sup>177</sup>Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. *Eur J Nucl Med Mol Imaging*. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Review.
25. Lang D, Huber H, Kaiser B, Virgolini I, Lamprecht B, Gabriel M. SUV as a Possible Predictor of Disease Extent and Therapy Duration in Complex Tuberculosis. *Clin Nucl Med*. 2018 Feb;43(2):94-100.
26. Prause M, Niedermoser S, Wängler C, Decristoforo C, Seibold U, Riester S, Taguchi T, Schirmacher R, Fricker G, Wängler B. Synthesis, in vitro and in vivo evaluation of <sup>18</sup>F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. *Nucl Med Biol*. 2018 Feb;57:1-11.
27. Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom J, Orlova A, Tolmachev V, Decristoforo C. Cyclic versus Noncyclic Chelating Scaffold for <sup>89</sup>Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. *Mol Pharm*. 2018 Jan 2;15(1):175-185.